Why ABVC BioPharma, Inc.’s (ABVC) Stock Is Down 14.36%
As of Thursday, July 09, ABVC BioPharma, Inc.’s ABVC share price has dipped by 14.36%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Commentary & Analysis
Why ABVC BioPharma, Inc.’s (ABVC) Stock Is Down 17.57%
As of Thursday, July 09, ABVC BioPharma, Inc.’s ABVC share price has dipped by 17.57%, which has investors questioning if this is right time to buy.Omar Beirat
Why ABVC BioPharma, Inc.’s (ABVC) Stock Is Down 7.34%
As of Monday, January 12, ABVC BioPharma, Inc.’s ABVC share price has dipped by 7.34%, which has investors questioning if this is right time to buy.Jenna Brashear
Why ABVC BioPharma, Inc.’s (ABVC) Stock Is Up 6.01%
As of Friday, December 26, ABVC BioPharma, Inc.’s ABVC share price has surged by 6.01%, which has investors questioning if this is right time to sell.Jenna Brashear
Why ABVC BioPharma, Inc.’s (ABVC) Stock Is Up 11.40%
As of Monday, December 22, ABVC BioPharma, Inc.’s ABVC share price has surged by 11.40%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ABVC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $29.6 | $259.1 | 12% |
|
| Shares Out (Mil) | 26.1 | 54.3 | 34% |
|
| Institutional Ownership | 18.7% | 92.8% | 9% |
|
| Float (Mil) | 21.1 | 42.0 | 30% |
|
| Beta | 0.63 | 0.95 | 37% |
|
| Avg Daily Volume (000s) | 162 | 637 | 40% |
|
| Price Change (52-week) |
(60.3%) | 52.5% | 13% |
|
| Growth | ABVC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | 4.2% | (10.1%) | 46% |
|
| EPS (5yr) | 39.9% | 15.8% | 89 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (61.8%) | (15.6%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ABVC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($7) | ($43) | 31% |
|
| EPS (TTM) | ($0.285) | ($1.600) | 31% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($32) | 28% |
|
| Net Cash Flow (TTM) (Mil) | ($1) | $2 | 40% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 18% |
|
| Enterprise Value (Q1) (Mil) | $28 | $175 | 13% |
|
| Valuation | ABVC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.85 | 2.54 | 64% |
|
| P/E | na | 18.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ABVC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (39.9%) | (47.5%) | 14% |
|
| ROE | (82.2%) | (54.9%) | 11% |
|
| Liabilities to Assets | 36.8% | 29.4% | 28% |
|
| F-Score | 1 | 3 | 1% |
|
ABVC BioPharma, Inc. did not pass any screens on 9/23/2026.
